Voyageur Pharmaceuticals Ltd. (TSXV: VM) has achieved its first milestone under its Collaboration and Funding Agreement with Bayer AG, triggering a USD $1,000,000 non-dilutive payment. The milestone was reached after Voyageur successfully submitted a complete feasibility work plan and timetable, which Bayer has approved. Combined with an initial USD $350,000 received on March 31, 2026, total funding from Bayer now stands at USD $1,350,000 of the committed USD $2,350,000, marking a significant step toward establishing a domestic North American iodine supply for contrast media manufacturing.

Key Points

  • Voyageur Pharmaceuticals Ltd. (TSXV: VM / OTC Pink: VYYRF) is a Calgary-based pharmaceutical company focused on barium and iodine contrast media.
  • The company achieved its first milestone under the Bayer AG Collaboration and Funding Agreement, unlocking a USD $1,000,000 non-dilutive payment.
  • Total Bayer funding received to date is USD $1,350,000; a remaining Milestone Payment II of USD $1,000,000 is expected upon completion of the FEL-3 feasibility study.
  • Investors may be watching for progress on the transportable pilot plant, scheduled to begin field operations this fall, and subsequent FEL-3 study completion.

Mueller Iodine Extraction Process Delivers 99.8% Purity Confirmation

Voyageur's research and development team in Houston has successfully demonstrated the company's proprietary patent-pending Mueller iodine extraction process. The release states the process produced laboratory iodine at 99.8% purity from Anadarko Basin produced water, providing the technical confirmation Bayer required to advance the program. A transportable pilot plant for the iodine extraction process is nearing completion and is scheduled to begin field operations this fall. The announcement notes the process underpins Voyageur's strategy to develop a reliable, high-purity North American iodine source for use in contrast media drugs.

Fluor Corporation Engineering Support and FEL Study Progress

Fluor Corporation (NYSE: FLR), a global engineering firm, has been providing engineering, thermodynamic modelling, and project planning support for the program. The disclosure states engineering phases are progressing through FEL-2 (Concept Design) and FEL-3 (Basic Design) to define a practical demonstration-scale configuration for the modular Field Unit and Central Hub architecture. FEL-2 is expected to take approximately four to five months, followed by FEL-3, which is expected to take approximately seven to nine months. The non-dilutive funding will support ongoing feasibility work through 2026, the release states.

Vertically Integrated Radiology Drug Supply Chain Strategy and Bayer Offtake Potential

Following successful feasibility study completion, Bayer and Voyageur may explore a second phase to negotiate a long-term offtake supply agreement. The project outlines a potential production of 1,000 tonnes per year of iodine, with a phased rollout beginning at 200 tonnes per year. The company's vertically integrated strategy, which also encompasses the Frances Creek barium sulfate project and five Health Canada-licensed barium contrast products, aims to reduce reliance on imported raw materials. The global contrast media market is estimated at approximately USD $7.06 billion, according to the announcement.